Loading…
Loading…
research
Adverum Biotechnologies is a clinical-stage gene therapy company based in Redwood City, California. Founded in 2012, the company focuses on developing innovative therapies for prevalent ocular diseases, particularly wet age-related macular degeneration (wet AMD). Adverum aims to establish gene therapy as a new standard of care, with the goal of restoring vision and preventing blindness. The company's lead product, ixoberogene soroparvovec (Ixo-vec), is an investigational one-time gene therapy designed to treat neovascular (wet) AMD. Utilizing a proprietary adeno-associated virus (AAV) vector platform, Ixo-vec transforms retinal cells into "biofactories" that produce aflibercept, potentially extending treatment benefits and reducing the need for frequent injections. Adverum also develops therapies for rare conditions, such as blue-cone monochromacy, through its advanced AAV vector technology. The company was acquired by Eli Lilly and Company in 2025, marking a significant partnership in its mission to address serious ocular diseases.
Adverum Biotechnologies is a clinical-stage gene therapy company based in Redwood City, California. Founded in 2012, the company focuses on developing innovative therapies for prevalent ocular diseases, particularly wet age-related macular degeneration (wet AMD). Adverum aims to establish gene therapy as a new standard of care, with the goal of restoring vision and preventing blindness. The company's lead product, ixoberogene soroparvovec (Ixo-vec), is an investigational one-time gene therapy designed to treat neovascular (wet) AMD. Utilizing a proprietary adeno-associated virus (AAV) vector platform, Ixo-vec transforms retinal cells into "biofactories" that produce aflibercept, potentially extending treatment benefits and reducing the need for frequent injections. Adverum also develops therapies for rare conditions, such as blue-cone monochromacy, through its advanced AAV vector technology. The company was acquired by Eli Lilly and Company in 2025, marking a significant partnership in its mission to address serious ocular diseases.
Adverum has been mentioned across 3 podcasts.
Represent this company? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
